CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity

Maruyama, Takahisa; Yamamoto, Yasuo; Kano, Yuko; Kurazono, Mizuyo; Matsuhisa, Eiji; Takata, Hiromi; Takata, Toshihiko; Atsumi, Kunio; Iwamatsu, Katsuyoshi; Shitara, Eiki

doi:10.1016/j.bmc.2007.06.057

Cited by 10 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients who are immunocompromised, pooled IV immunoglobulin may be used in addition to antibiotic therapy. A new carbapenem (ie, CP5484) has excellent anti‐MRSA activity, 42 and a new bacterial product called pumilicin also has a high level of activity against both MRSA and vancomycin‐resistant enterococcus. An herbal product harvested from the Atuna racemosa tree has been shown to inhibit MRSA on topical application 43 …”

Section: Bacteriology and Epidemiologymentioning

confidence: 99%

Methicillin‐ResistantStaphylococcus aureus: An Update

Durai¹,

Ng²,

Hoque³

2010

AORN Journal

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus (MRSA) is a serious threat to patients in health care facilities and the community. A MRSA infection can be much more severe than other bacterial infections and can be life-threatening. Resistance to common antibiotics makes treating MRSA costly and difficult. Prolonged hospitalization requiring specialized IV antibiotics also has cost implications. Treatment of MRSA can include use of antibiotics; topical therapies such as honey, topical silver, and gentian violet; and bacteriophages. Research is being conducted on new antibiotics and a MRSA vaccine.

show abstract

Section: Bacteriology and Epidemiologymentioning

confidence: 99%

Methicillin‐ResistantStaphylococcus aureus: An Update

Durai¹,

Ng²,

Hoque³

2010

AORN Journal

View full text Add to dashboard Cite

show abstract

“…In general, doripenem is well tolerated [120]. The most common adverse event reported was headache, which was observed in 33% and 50% of patients who received 500 mg every 8 hours and 1000 mg every 8 hours, respectively, versus 13% in the comparator recipients [121].…”

Section: Doripenemmentioning

confidence: 99%

Current Status of Newer Carbapenems

Bassetti

Nicolini

Esposito

et al. 2009

CMC

View full text Add to dashboard Cite

show abstract

“…Ciprofoxacin (1), norfoxacin (2) and enoxacin (3) are characterized by having a piperazine moiety at C-7, which represents a site amenable to significant modification ( Figure 2). Thiazole moiety has diverse utility as antimicrobial [14], antioxidant [15], CNS agent [16], anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and reduced toxicity [17]. The thiazole derivatives act as in vitro anti-HIV activity and antiretroviral agents [18].…”

Section: Introductionmentioning

confidence: 99%

“…The thiazole derivatives act as in vitro anti-HIV activity and antiretroviral agents [18]. Thiazole moiety containing compounds showed the activities against methicillin-resistant Staphylococcus aureus (MRSA) [17].…”

Section: Introductionmentioning

confidence: 99%

<b>Syntheses and spectral studies of novel ciprofloxacin derivatives</b>

Yadav

Joshi

2008

Bull. Chem. Soc. Eth.

View full text Add to dashboard Cite

Reaction of 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (ciprofloxacin) with thiazole/benzothiazole diazonium chloride afforded piperazine substituted ciprofloxacin derivative. The acid part of these derivatives was further condensed with various β-diketones to get 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(thiazol-2-yldiazenyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid derivatives (5ae) and 7-(4-(benzo[d]thiazol-2-yldiazenyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3carboxylic acid derivatives (5f-j). Structures of these compounds were established on the basis of spectral studies.

show abstract

CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity

Cited by 10 publications

References 12 publications

Methicillin‐ResistantStaphylococcus aureus: An Update

Methicillin‐ResistantStaphylococcus aureus: An Update

Current Status of Newer Carbapenems

<b>Syntheses and spectral studies of novel ciprofloxacin derivatives</b>

Contact Info

Product

Resources

About